These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Author: Wiegratz I, Jung-Hoffmann C, Gross W, Kuhl H.
    Journal: Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262.
    Abstract:
    The effect of a triphasic oral contraceptive containing ethinyl estradiol and gestodene (EE/GSD) on various lipid and lipoprotein parameters was compared with that of a monophasic formulation containing 35 micrograms ethinyl estradiol and 250 micrograms norgestimate (EE/NGM). Blood samples were collected from 46 women on days 2, 11, and 21 of the preceding control cycle and of the third, sixth, and twelfth treatment cycles. There was no significant difference between formulations with regard to the influence on any measured parameter. As compared with controls, a significant increase was observed in the plasma levels of total triglycerides (24-78%), total phospholipids (7-20%), very low density lipoprotein (VLDL) triglycerides (61-76%), VLDL-phospholipids (14-60%), low density lipoprotein (LDL) triglycerides (8-35%), LDL-phospholipids (28-30%), high density lipoprotein (HDL) cholesterol (8-16%), HDL 3-cholesterol (11-20%), HDL-triglycerides (17-66%), HDL-phospholipids, HDL 3-phospholipids (7-11%), apolipoprotein (apo) A-I (5-20%) and apo A-II (10-40%) during treatment with both formulations. In contrast, the LDL-cholesterol levels were significantly decreased. These changes in lipid metabolism appear to reflect a predominance of the effect of the estrogen component. The results indicate that both low dose oral contraceptives containing different progestins and different amounts of EE do not exert a deleterious effect on lipoprotein metabolism, as high HDL-cholesterol and low LDL-cholesterol levels are known as low risk factors of cardiovascular disease. In contrast to endogenous hypertriglyceridemia, an EE-induced rise in triglyceride levels does not appear to increase cardiovascular risk if LDL is not increased. Oral contraceptives (OCs) that contain a progestogen with high androgenic activity have been shown to have an atherogenic effect on lipid and lipoprotein metabolism. The present study compared the effect of a triphasic OC containing ethinyl estradiol and gestodene on selected lipid and lipoprotein parameters with that of a monophasic OC containing 35 mcg of ethinyl estradiol and 250 mcg of norgestimate. 46 healthy volunteers from Frankfurt, Germany, were enrolled and randomly assigned to receive one of the two OCs. Serum samples were collected on days 2, 11, and 21 of the control cycle and treatment cycles 3, 6, and 12. No significant differences between formulations were observed for any of the measured parameters. Significant increases were recorded during OC use in plasma levels of total triglycerides (24-78%), total phospholipids (7-20%), very low density lipoprotein (VLDL) triglycerides (61-76%), VLDL phospholipids (14-60%), low density lipoprotein (LDL) triglycerides (8-35%), LDL phospholipids (28-30%), high density lipoprotein (HDL) cholesterol (8-16%), HDL 3-cholesterol (11-20%), HDL triglycerides (17-66%), HDL phospholipids (7-11%), apolipoprotein (apo) A-I (5-20%), and apo A-II (10-40%). In contrast, LDL-cholesterol levels were significantly decreased during treatment with both formulations. These changes appear to reflect a predominance of the effect of the estrogen component.
    [Abstract] [Full Text] [Related] [New Search]